Market Closed -
Nasdaq
04:00:00 2024-05-10 pm EDT
5-day change
1st Jan Change
65.48
USD
-3.02%
-6.92%
-11.02%
Nuvalent, Inc.(NasdaqGS:NUVL) added to S&P TMI Index
September 20, 2021 at 12:00 am EDT
Nuvalent, Inc.(NasdaqGS:NUVL) added to S&P TMI Index
Nuvalent Q1 Net Loss Widens
May. 09
MT
Nuvalent, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 09
CI
Nuvalent Insider Sold Shares Worth $2,605,525, According to a Recent SEC Filing
May. 08
MT
Nuvalent Insider Sold Shares Worth $2,666,555, According to a Recent SEC Filing
May. 01
MT
Nuvalent Insider Sold Shares Worth $2,458,335, According to a Recent SEC Filing
Apr. 17
MT
Jefferies Initiates Nuvalent With Buy Rating, $97 Price Target
Apr. 17
MT
Nuvalent Insider Sold Shares Worth $2,566,479, According to a Recent SEC Filing
Apr. 10
MT
North American Morning Briefing : Stocks Seen -2-
Apr. 02
DJ
Nuvalent Insider Sold Shares Worth $1,654,311, According to a Recent SEC Filing
Apr. 01
MT
Leerink Partners Upgrades Nuvalent to Outperform From Market Perform, Raises Price Target to $110 From $69
Apr. 01
MT
Nuvalent Insider Sold Shares Worth $3,032,528, According to a Recent SEC Filing
Mar. 27
MT
Nuvalent Insider Sold Shares Worth $1,550,229, According to a Recent SEC Filing
Mar. 25
MT
BMO Capital Raises Price Target on Nuvalent to $102 From $93, Maintains Outperform Rating
Feb. 28
MT
Nuvalent's Non-Small Cell Lung Cancer Drug Candidate Gets FDA Breakthrough Therapy Designation
Feb. 27
MT
Nuvalent, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Feb. 27
CI
Nuvalent, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Feb. 27
CI
Baird Initiates Nuvalent With Outperform Rating, Price Target is $105
Feb. 23
MT
Nuvalent Starts Phase 2 Part of Clinical Trial of Potential Lung Cancer Treatment
Feb. 12
MT
Wedbush Raises Nuvalent's Price Target to $99 From $82, Maintains Outperform Rating
Feb. 12
MT
Nuvalent, Inc. Initiates the Phase 2 Portion of Alkove-1 Clinical Trial for Patients with Alk-Positive Nsclc and Other Solid Tumors
Feb. 12
CI
Nuvalent Outlines Three-Year Product Plan
Jan. 08
MT
Wedbush Raises Nuvalent's PT to $82 From $74 After Announced 3-Year Plan to Place At Least One Lead Asset on Market by 2026; Keeps Outperform Rating
Jan. 08
MT
Nuvalent Insider Sold Shares Worth $378,350, According to a Recent SEC Filing
Dec. 21
MT
Nuvalent Insider Sold Shares Worth $2,274,600, According to a Recent SEC Filing
Dec. 21
MT
Nuvalent Insider Sold Shares Worth $2,880,548, According to a Recent SEC Filing
Dec. 21
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases and drive more durable responses. It is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, NVL-520, is being developed for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, NVL-655, is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC. LC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor.
More about the company
Last Close Price
65.48
USD
Average target price
101.1
USD
Spread / Average Target
+54.42%
Consensus
1st Jan change
Capi.
-11.02% 4.35B +17.96% 47.02B +48.77% 41.86B +1.17% 41.76B -4.27% 28.8B +11.42% 26.05B -21.39% 19.15B +4.86% 12.55B +27.29% 12.34B -3.50% 11.82B
Other Biotechnology & Medical Research
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
NUVALENT, INC. 
